Pfizer, Astellas tout positive PhIII data to potentially expand Xtandi label
Pfizer and Astellas are gunning to add a fourth indication to their cancer drug Xtandi with Phase III trial results released …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.